As a response to cholestasis, many patients with PSC with advanced disease will have progressed beyond a ‘tipping point’, whereby bile acid synthesis is fully suppressed and any further therapeutic activation of the FXR–FGF19 axis will be futile. This evidence concerns the gene NR1H4 and cholestasis.